Pliant Therapeutics Statistics
Total Valuation
PLRX has a market cap or net worth of $921.17 million. The enterprise value is $491.96 million.
| Market Cap | 921.17M |
| Enterprise Value | 491.96M |
Important Dates
The last earnings date was Monday, May 6, 2024, after market close.
| Earnings Date | May 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
PLRX has 60.33 million shares outstanding. The number of shares has increased by 7.36% in one year.
| Shares Outstanding | 60.33M |
| Shares Change (YoY) | +7.36% |
| Shares Change (QoQ) | +0.44% |
| Owned by Insiders (%) | 6.33% |
| Owned by Institutions (%) | 115.66% |
| Float | 46.34M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3,714.42 |
| Forward PS | 349.19 |
| PB Ratio | 2.11 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1,983.71 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 16.12, with a Debt / Equity ratio of 0.12.
| Current Ratio | 16.12 |
| Quick Ratio | n/a |
| Debt / Equity | 0.12 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -120.79 |
Financial Efficiency
Return on equity (ROE) is -35.10% and return on invested capital (ROIC) is -39.52%.
| Return on Equity (ROE) | -35.10% |
| Return on Assets (ROA) | -31.80% |
| Return on Capital (ROIC) | -39.52% |
| Revenue Per Employee | $1,570 |
| Profits Per Employee | -$1.08M |
| Employee Count | 158 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -29.08% in the last 52 weeks. The beta is 1.20, so PLRX's price volatility has been higher than the market average.
| Beta (1Y) | 1.20 |
| 52-Week Price Change | -29.08% |
| 50-Day Moving Average | 14.00 |
| 200-Day Moving Average | 15.69 |
| Relative Strength Index (RSI) | 63.94 |
| Average Volume (30 Days) | 372,730 |
Short Selling Information
The latest short interest is 7.55 million, so 12.51% of the outstanding shares have been sold short.
| Short Interest | 7.55M |
| Short Previous Month | 7.62M |
| Short % of Shares Out | 12.51% |
| Short % of Float | 16.28% |
| Short Ratio (days to cover) | 23.42 |
Income Statement
In the last 12 months, PLRX had revenue of $248,000 and -$170.74 million in losses. Loss per share was -$2.87.
| Revenue | 248,000 |
| Gross Profit | 248,000 |
| Operating Income | -194.44M |
| Pretax Income | -170.74M |
| Net Income | -170.74M |
| EBITDA | -164.98M |
| EBIT | -169.34M |
| Loss Per Share | -$2.87 |
Balance Sheet
The company has $483.87 million in cash and $54.66 million in debt, giving a net cash position of $429.22 million or $7.11 per share.
| Cash & Cash Equivalents | 483.87M |
| Total Debt | 54.66M |
| Net Cash | 429.22M |
| Net Cash Per Share | $7.11 |
| Equity / Book Value | 437.33M |
| Book Value Per Share | 7.25 |
| Working Capital | 459.51M |
Cash Flow
In the last 12 months, operating cash flow was -$116.36 million and capital expenditures -$2.25 million, giving a free cash flow of -$118.61 million.
| Operating Cash Flow | -116.36M |
| Capital Expenditures | -2.25M |
| Free Cash Flow | -118.61M |
| FCF Per Share | -$1.97 |
Margins
Gross margin is 100.00%, with operating and profit margins of -78,404.03% and -68,847.98%.
| Gross Margin | 100.00% |
| Operating Margin | -78,404.03% |
| Pretax Margin | -68,847.98% |
| Profit Margin | -68,847.98% |
| EBITDA Margin | -66,522.98% |
| EBIT Margin | -68,282.66% |
| FCF Margin | -47,825.00% |
Dividends & Yields
PLRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.36% |
| Shareholder Yield | -7.36% |
| Earnings Yield | -18.54% |
| FCF Yield | -12.88% |
Analyst Forecast
The average price target for PLRX is $46.25, which is 202.88% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $46.25 |
| Price Target Difference | 202.88% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 161.39% |
| EPS Growth Forecast (5Y) | -16.29% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
PLRX has an Altman Z-Score of 5.08 and a Piotroski F-Score of 1.
| Altman Z-Score | 5.08 |
| Piotroski F-Score | 1 |